Abstract
Aims and background: Goserelin is a gonadotrophin-releasing hormone (GnRH) analogue that induces the suppression of gonadal steroidogenesis, and it could therefore be a medical alternative to irreversible surgical castration. We report the clinical and endocrine results from 40 goserelin-treated premenopausal patients with advanced breast cancer. Methods: A depot formulation of the drug (3.6 mg s.c.) was administered fortnightly for the first 4 doses, and monthly thereafter. Gonadotrophins and estradiol (E2) levels were measured before and at specific times during the treatment. Results: Objective responses were observed in 17 of the 38 evaluable patients (45%), six of whom achieved complete remission. The best responses were observed on soft tissues (65%). Castration E2 levels were achieved in all of the patients. Conclusions: Our results confirm that goserelin is as effective as surgical oophorectomy in premenopausal advanced breast cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 28-32 |
| Number of pages | 5 |
| Journal | Tumori |
| Volume | 80 |
| Issue number | 1 |
| Publication status | Published - 1994 |
Keywords
- breast cancer
- GnRH analogue
- medical castration
ASJC Scopus subject areas
- Cancer Research